Verucerfont
- Generic Name
- Verucerfont
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26N6O2
- CAS Number
- 885220-61-1
- Unique Ingredient Identifier
- X60608B091
- Background
Verucerfont has been used in trials studying the treatment of Congenital Adrenal Hyperplasia.
Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- Neurocrine Biosciences
- Registration Number
- NCT02349503
Analyzing Female Trauma Exposed Responses to a Medication
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 128
- Registration Number
- NCT01814332
- Locations
- πΊπΈ
San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States
CRF1 Antagonist GSK561679 in Alcoholism
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Target Recruit Count
- 44
- Registration Number
- NCT01187511
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Emory University
- Target Recruit Count
- 267
- Registration Number
- NCT01018992
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
πΊπΈStress and Health Research Program, San Francisco VA Medical Center, University of California San Francisco, San Francisco, California, United States
πΊπΈMount Sinai School of Medicine, New York, New York, United States
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00733980
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
- Conditions
- Depressive Disorder and Anxiety Disorders
- Interventions
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00426608
- Locations
- π¬π§
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.